Pfizer announced on Thursday that they haven’t seen any evidence that circulating variants of the coronavirus result in a loss of the protection provided by the vaccine they developed with BioNTech, as reported by Reuters.
“We haven’t observed changes to neutralizing antibody levels that would predict a significant reduction in protection given by 2 doses of BNT162B2,” Pfizer noted.